{"schema_version":"secwatch.filing_event.v1","accession":"0001434647-26-000067","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2026-08-05T20:13:22+00:00","discovered_at":"2026-08-05T20:14:01.275068+00:00","generated_at":"2026-08-05T20:14:09.578851+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra Q2 2026 net revenue $39.7M, up 53% YoY; MIPLYFFA drives growth","bullets":["Net revenue $39.7M, including $30.2M from MIPLYFFA; up from $25.9M in Q2 2025.","Net income $8.8M ($0.14 per share); adjusted net income $15.2M ($0.25 per share).","Cash, cash equivalents and investments $260.2M as of June 30, 2026.","14 MIPLYFFA prescription enrollment forms in Q2; total 184 since launch; 69% covered lives.","66 patients enrolled in Phase 3 DiSCOVER trial for celiprolol; EU MAA re-examination requested."],"urls":{"canonical":"https://secwatch.observer/filing/0001434647-26-000067","json":"https://secwatch.observer/filing/0001434647-26-000067.json","markdown":"https://secwatch.observer/filing/0001434647-26-000067.md","text":"https://secwatch.observer/filing/0001434647-26-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000067/0001434647-26-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000067/zvra-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:14:09.578851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}